HIV molecular immunology database
MICSAAEKLWVTVYYGVP
|
gp160(26-43) | human epitope |
NTAENLWVTVYYGVP
|
gp160(29-43) | B*44:02 human epitope |
SATEKLWVTVYYGVP
|
gp160(29-43) | human epitope |
AVEKLWVTVYY
|
gp160(30-40) | B*18:01 humanized mouse epitope |
AiEKLWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AaEKLWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AeEKLWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AVkKLWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AVgKLWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AVEKsWVTVYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AVEKLWVTiYY
|
gp160(30-40) | escape documented in this paper; inferred escape; observed variant |
AAENLWVTVYY
|
gp160(30-40) | B*44 human epitope |
AENLVWTVYY
|
gp160(30-40) | B44 human epitope |
AVEKLWVTVYYGVPA
|
gp160(30-44) | mouse epitope |
VMGNLWVTVYYGVPVWK
|
gp160(30-46) | C*07 human epitope |
AAENLWVTVYYGVPVWK
|
gp160(30-46) | human epitope |
vggNLWVTVYYGVPVWK
|
gp160(30-46) | subtype-specific susceptible form |
AAEQLWVTVYYGVPVWKEAT
|
gp160(30-49) | A11 human epitope |
AAEQLWVTVYYGVPVWKEAT
|
gp160(30-49) | A11 human epitope |
ATEKLWVTVYYGVPVWKEAT
|
gp160(30-49) | human epitope |
ATEKmWVTVYYGVPVWKEAT
|
gp160(30-49) | observed variant |
ATEKLWVTVYYGaPVWKEAT
|
gp160(30-49) | observed variant |
ATEKLcVTVYYGVPVWKEAT
|
gp160(30-49) | observed variant |
ATEKLWVTVhYGVPVWKEAT
|
gp160(30-49) | observed variant |
ATEKLWVTVYYGVPaWKEAT
|
gp160(30-49) | observed variant |
ATEKLWVTVYhGVPVWKEAT
|
gp160(30-49) | observed variant |
AENLWVTVY
|
gp160(31-39) | B*15:17 human epitope |
AENLWVTVY
|
gp160(31-39) | B*15:40 human epitope |
AENLWVTVY
|
gp160(31-39) | B*18 human epitope |
AENLWVTVY
|
gp160(31-39) | B*18:01 human epitope |
AENLWVTVY
|
gp160(31-39) | B*18:01 human epitope |
AdNLWVTVY
|
gp160(31-39) | susceptible form |
tdNLWVTVY
|
gp160(31-39) | susceptible form |
tEdLWVTVY
|
gp160(31-39) | escape documented in this paper |
eEdLWVTVY
|
gp160(31-39) | escape documented in this paper |
AEdsWVTVY
|
gp160(31-39) | escape documented in this paper |
AENLWVTVY
|
gp160(31-39) | B*18:01 human epitope |
TEdLWVTVY
|
gp160(31-39) | escape documented in this paper |
eEDLWVTVY
|
gp160(31-39) | escape documented in this paper |
AEdsWVTVY
|
gp160(31-39) | escape documented in this paper |
AENLWVTVY
|
gp160(31-39) | B*18:01 human epitope |
AdNLWVTVY
|
gp160(31-39) | susceptible form |
AEdsWVTVY
|
gp160(31-39) | escape documented in this paper |
AENLWVTVY
|
gp160(31-39) | B*44 human epitope |
AENLWVTVY
|
gp160(31-39) | B*44 human epitope |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
tENLWVTVY
|
gp160(31-39) | susceptible form |
AkNLWVTVY
|
gp160(31-39) | non-susceptible form |
AgNLWVTVY
|
gp160(31-39) | non-susceptible form |
AaNLWVTVY
|
gp160(31-39) | non-susceptible form |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
AENLWVTVY
|
gp160(31-39) | B44 human epitope |
AENLWVTVY
|
gp160(31-39) | B*44:03 human epitope |
AaNLWVTaY
|
gp160(31-39) | diminished response |
AEkLWVTVY
|
gp160(31-39) | diminished response |
AENLgVTVY
|
gp160(31-39) | diminished response |
tENLWVTVY
|
gp160(31-39) | susceptible form |
vENsWVTVY
|
gp160(31-39) | diminished response |
tEkLWVTVY
|
gp160(31-39) | diminished response |
AgNLWVTVY
|
gp160(31-39) | diminished response |
AaNLWVTVY
|
gp160(31-39) | escape documented in this paper |
AkNLWVTVY
|
gp160(31-39) | escape documented in this paper |
tENLWVTiY
|
gp160(31-39) | susceptible form |
AENLWVTVY
|
gp160(31-39) | B*44:03 human epitope |
AEkLWVTVY
|
gp160(31-39) | escape documented in this paper |
tENLWVTVY
|
gp160(31-39) | susceptible form |
vENLWVTVY
|
gp160(31-39) | inferred escape |
AkNLWVTVY
|
gp160(31-39) | escape documented in this paper |
AgNLWVTVY
|
gp160(31-39) | escape documented in this paper |
AENLWVTiY
|
gp160(31-39) | observed variant |
AEdLWVTVY
|
gp160(31-39) | observed variant |
AaNLWVTVY
|
gp160(31-39) | escape documented in this paper |
AEsLWVTVY
|
gp160(31-39) | observed variant |
AdNLWVTVY
|
gp160(31-39) | observed variant |
AaNLWVTaY
|
gp160(31-39) | escape documented in this paper |
AENsWVTVY
|
gp160(31-39) | observed variant |
vENsWVTVY
|
gp160(31-39) | escape documented in this paper |
AEtLWVTVY
|
gp160(31-39) | observed variant |
tENLWVTiY
|
gp160(31-39) | susceptible form |
tEkLWVTVY
|
gp160(31-39) | escape documented in this paper |
AENLWVTVY
|
gp160(31-39) | C*02 human epitope |
AENLWVTVY
|
gp160(31-39) | human epitope |
AENLWVTVYY
|
gp160(31-40) | A*29 human epitope |
AENLWVTVYY
|
gp160(31-40) | A*68:02 human epitope |
AENLWVTVYY
|
gp160(31-40) | B*18 human epitope |
AENLWVTVYY
|
gp160(31-40) | B*44:02 human epitope |
AENLWVTVYY
|
gp160(31-40) | C*04 human epitope |
TEKLWVTVYYGVPVWKEATTTLFCA
|
gp160(31-55) | B18 human epitope |
TEKLWVTVYYGVPVWKEATTTLFCA
|
gp160(31-55) | B18 human epitope |
DNLWVTVYY
|
gp160(32-40) | B44 human epitope |
EKLWVTVYY
|
gp160(32-40) | C*06:02, C*07:02 human epitope |
ENLWVTVYY
|
gp160(32-40) | human epitope |
EQLWVTVYYGVPVWKEATTT
|
gp160(32-51) | human epitope |
KLWVTVYYGV
|
gp160(33-42) | A*02:01 human epitope |
KLWVTVYYGV
|
gp160(33-42) | A*02:01 human epitope |
KLWVTVYYGV
|
gp160(33-42) | A*02:01 human epitope |
KLWVTVYYGV
|
gp160(33-42) | A2 human epitope |
nwWVTVYYGV
|
gp160(33-42) | observed variant |
NLWVTVYYGV
|
gp160(33-42) | A2 human epitope |
NLWVTVYYGV
|
gp160(33-42) | A2 human epitope |
kLWVTVYYGV
|
gp160(33-42) | observed variant |
qLWVTVYYGV
|
gp160(33-42) | observed variant |
dLWVTVYYGV
|
gp160(33-42) | observed variant |
LWVTVYYGV
|
gp160(34-42) | A*02:01 human epitope |
LWVTVYYGV
|
gp160(34-42) | A*02:01 human epitope |
LWVTVYYGV
|
gp160(34-42) | A*02:01 human epitope |
LWVTVYYGVPVWKDA
|
gp160(34-48) | A*03:01 human epitope |
LWVTVYYGVPVWKEAKTT
|
gp160(34-51) | human epitope |
LWVTVYYGVPVWKEATTTLFCA
|
gp160(34-55) | A2 human epitope |
LWVTVYYGVPVWKEATTTLFCA
|
gp160(34-55) | A2 human epitope |
wWVTVYYGVPVWKEATnTLFCA
|
gp160(34-55) | observed variant |
VTVYYGVPV
|
gp160(36-44) | A2 human epitope |
VTVYYGVPV
|
gp160(36-44) | A2 human epitope |
VTVYYGVPV
|
gp160(36-44) | A2 human epitope |
VTVYYGVPVWK
|
gp160(36-46) | A*03:01 human epitope |
VTVYYGVPVWR
|
gp160(36-46) | A*11 human epitope |
VTVYYGVPVWR
|
gp160(36-46) | A11 human epitope |
VTVYYGVPVWK
|
gp160(36-46) | A*68:01, A11 human epitope |
VTVYYGVPVWK
|
gp160(36-46) | A*11:01 human, mouse epitope |
VTVYYGVPVWr
|
gp160(36-46) | susceptible form |
VTiYYGVPVWK
|
gp160(36-46) | susceptible form |
VTVYdGVPVWK
|
gp160(36-46) | non-susceptible form |
VTVYYGVPiWK
|
gp160(36-46) | susceptible form |
iTVYYGVPVWr
|
gp160(36-46) | susceptible form |
VTiYYGVPVWr
|
gp160(36-46) | susceptible form |
VTVYdGVPVWr
|
gp160(36-46) | non-susceptible form |
VTVYYGiPVWr
|
gp160(36-46) | susceptible form |
VTVYYGVPVrr
|
gp160(36-46) | non-susceptible form |
VTVYYGVPVWK
|
gp160(36-46) | A3 human epitope |
VTVYYGVPVWK
|
gp160(36-46) | A3 supertype human, mouse epitope |
VTVYYGVPVWK
|
gp160(36-46) | A*68:01 human epitope |
VTVYYGVPVWr
|
gp160(36-46) | observed variant |
VTVYYGVPVWKE
|
gp160(36-47) | A*03, A*11, A*68:01, C*07 human epitope |
TVYYGVPVW
|
gp160(37-45) | A*03, A*11 human epitope |
TVYYGVPVW
|
gp160(37-45) | B*35:01 human epitope |
TVYYGVPVW
|
gp160(37-45) | B*57:03, B*58:01 human epitope |
TVYYGIPVW
|
gp160(37-45) | human epitope |
TVYYGVPVW
|
gp160(37-45) | human epitope |
TVYYGVPVW
|
gp160(37-45) | human epitope |
TVYYGVPMW
|
gp160(37-45) | human epitope |
TVYYGVPVW
|
gp160(37-45) | human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*02, A*11 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03, A*11 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TiYYGVPVWK
|
gp160(37-46) | diminished response; escape documented in this paper; susceptible form |
TiYYGVPVWr
|
gp160(37-46) | diminished response; escape documented in this paper; susceptible form |
TVYYGVPagr
|
gp160(37-46) | diminished response; escape documented in this paper; susceptible form |
TVhYGVPVWr
|
gp160(37-46) | diminished response; escape documented in this paper; non-susceptible form |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*03:01, A*68:01 human epitope |
TVYYGVPVWr
|
gp160(37-46) | observed variant |
TVYYGVPVWK
|
gp160(37-46) | A11 transgenic mouse epitope |
TVYYGVPVWK
|
gp160(37-46) | A11, A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A11, A3 human epitope |
TVYYGVPVMK
|
gp160(37-46) | A11, A3, A68 epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWr
|
gp160(37-46) | susceptible form; subtype-specific susceptible form |
TVYYGVPVWt
|
gp160(37-46) | susceptible form; subtype-specific susceptible form |
aVYYGVPVWK
|
gp160(37-46) | susceptible form; subtype-specific susceptible form |
AVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*32 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*34 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A*36 human epitope |
TVYYGVPVWK
|
gp160(37-46) | A3 supertype human epitope |
TVYYGVPVWK
|
gp160(37-46) | B*15:40 human epitope |
TVYYGVPVWK
|
gp160(37-46) | B*18 human epitope |
TVYYGVPVWK
|
gp160(37-46) | B*42:02 human epitope |
TVYYGVPVWK
|
gp160(37-46) | human epitope |
TVYYGVPVWKEAKTTLF
|
gp160(37-53) | A*32:01 human epitope |
TVYYGVPVWKEAKTTLF
|
gp160(37-53) | A*43:01 human epitope |
TVYYGVPVWKEAKTTLF
|
gp160(37-53) | B*58:01 human epitope |
TVYYGVPVWKEAKTTLF
|
gp160(37-53) | C*18 human epitope |
TVYYGVPVWKEATTTLF
|
gp160(37-53) | human epitope |
TVYYGVPVWKEAkTTLF
|
gp160(37-53) | subtype-specific susceptible form |
TVYYGVPVWKEATTTLF
|
gp160(37-53) | human epitope |
VYYGVPVWKEA
|
gp160(38-48) | Cw7 human epitope |
VYYGVPVWKEA
|
gp160(38-48) | Cw7 epitope |
VYYGVPVWrEA
|
gp160(38-48) | observed variant |
VYYGVPVWKEATTTL
|
gp160(38-52) | mouse epitope |
VYYGVPVWKEATTTL
|
gp160(38-52) | mouse epitope |
YYGVPVWKDAETTLF
|
gp160(39-53) | B*35:01, B*55:01 human epitope |
YYGVPVWKeAtTTLF
|
gp160(39-53) | susceptible form |
GVPVWKEATTT
|
gp160(41-51) | B*35 human epitope |
VPVWKEATT
|
gp160(42-50) | human epitope |
VPVWKEATTT
|
gp160(42-51) | A*68:02 human epitope |
VPVWKEATTT
|
gp160(42-51) | B*35:02, B*35:03, B*53:01 human epitope |
VPVWKEATTT
|
gp160(42-51) | B*39 human epitope |
VPVWKEATTT
|
gp160(42-51) | B55 human epitope |
VPVWKEATTT
|
gp160(42-51) | B55 human epitope |
VPVWKEATTT
|
gp160(42-51) | B55 human epitope |
VPVWKEATTT
|
gp160(42-51) | B*55:01, B55 human epitope |
VPVWKEAkTT
|
gp160(42-51) | observed variant |
VPVWrEAnTT
|
gp160(42-51) | observed variant |
VPVWKEATTT
|
gp160(42-51) | B*55:01 human epitope |
VPVWKEATTT
|
gp160(42-51) | B*81 human epitope |
VPVWKEATTT
|
gp160(42-51) | C*01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | A*23 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B35 human epitope |
VPVWKEAdTTL
|
gp160(42-52) | subtype-specific susceptible form |
VPVWrdAdTTL
|
gp160(42-52) | subtype-specific susceptible form |
VPVWKdAeTTL
|
gp160(42-52) | subtype-specific susceptible form |
VPVWKEATTTL
|
gp160(42-52) | B35 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35:01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35:01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35:01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*35:01 human epitope |
VPVWKEAkTTL
|
gp160(42-52) | observed variant |
VPVWKKATTTL
|
gp160(42-52) | B*35:01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*39 human epitope |
VPVWKEAKTTL
|
gp160(42-52) | B*53:01 human epitope |
VPVWKEAKTTL
|
gp160(42-52) | B*53:01 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*73 human epitope |
VPVWKEATTTL
|
gp160(42-52) | B*81 human epitope |
VPVWKEATTTL
|
gp160(42-52) | human epitope |
VPVWKEATTTL
|
gp160(42-52) | human epitope |
VPVWKEATTTLFCAS
|
gp160(42-56) | mouse epitope |
VPVWKEATTTLFCASDAK
|
gp160(42-59) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLsrASDAKAY
|
gp160(42-61) | observed variant |
aPVWKEATTTLFCASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFrASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFCvSDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFCAtDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFyASDAKAY
|
gp160(42-61) | observed variant |
VPVWKEATTTpFCASDAKAY
|
gp160(42-61) | observed variant |
VPaWKEATTTLFCASDAKsY
|
gp160(42-61) | observed variant |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VPVWKEATTTLFCASDAKAY
|
gp160(42-61) | human epitope |
VWKDAETTL
|
gp160(44-52) | B*38:01 human epitope |
VWKDAETTL
|
gp160(44-52) | human epitope |
VWKEATTTLF
|
gp160(44-53) | B55 human epitope |
VWKDAKTTLF
|
gp160(44-53) | human epitope |
VWKEATTTLF
|
gp160(44-53) | human epitope |
VWKDAETTLF
|
gp160(44-53) | human epitope |
VWKEATTTLF
|
gp160(44-53) | human epitope |
VWKDAETTLF
|
gp160(44-53) | human epitope |
VWKDAKTTLF
|
gp160(44-53) | human epitope |
VWKEAKTTLF
|
gp160(44-53) | human epitope |
KEATTTLFCASDAKA
|
gp160(46-60) | mouse epitope |